Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 11, 2026
Rocket Lab (RKLB) Delivers Record Revenue but Misses EPS Target in Q2 2026

Rocket Lab (RKLB) Delivers Record Revenue but Misses EPS Target in Q2 2026

Key Takeaways

  • Record quarterly revenue of $234.07 million, up 62% year-over-year, narrowly surpassing consensus estimates of approximately $231.6 million.
  • GAAP loss per share of $0.08 missed the consensus estimate of a $0.06 loss, driven in part by acquisition-related transaction costs.
  • Backlog reached an all-time high of $2.36 billion, surging 137% from the year-ago period, with more than $1 billion in new contracts already signed in the first weeks of Q3.
  • Adjusted EBITDA loss narrowed to $8.8 million from $27.6 million a year earlier, significantly outperforming management's own guidance range.
  • Neutron rocket development remains on schedule for pad delivery in Q4 2026, though CEO Peter Beck noted the window for a year-end maiden launch is narrowing.
  • Shares declined roughly 2% to 6% in after-hours trading as the earnings miss and softer near-term margin guidance tempered enthusiasm around record top-line growth.

Why This Quarter Matters

Rocket Lab's Q2 2026 report arrives at a pivotal moment for the end-to-end space company. The stock had already pulled back roughly 45% from its May 2026 high near $151, reflecting broader investor re-pricing across high-growth, high-valuation space names. At more than 65 times trailing sales, Rocket Lab entered this earnings print with little room for error. The quarter also represents the first reporting period incorporating the closed acquisitions of Mynaric and Motiv, adding new revenue streams and cost dynamics. Meanwhile, the pending $8 billion acquisition of Iridium Communications — announced in June and expected to close in mid-2027 — continues to reshape the long-term narrative. Investors were scrutinizing whether Rocket Lab could sustain its remarkable growth trajectory while demonstrating a credible path toward profitability.

Q2 Results in Detail

Rocket Lab reported Q2 2026 revenue of $234.07 million, a 62% increase from $144.5 million in the same quarter last year and a new company record, exceeding the $231.6 million consensus estimate. Product revenue surged 96% year-over-year to $181.3 million, while service revenue contributed $52.7 million. Space Systems generated $189.5 million, and Launch Services added $44.6 million.

On the bottom line, the company posted a GAAP net loss of $49.3 million, or $0.08 per share, improving from a loss of $66.4 million, or $0.13 per share, a year earlier. However, the per-share result missed the consensus estimate of a $0.06 loss, with the gap largely attributable to $8.6 million in transaction costs tied to the Mynaric and Motiv acquisitions and the pending Iridium deal.

Profitability metrics showed encouraging momentum. Adjusted EBITDA loss narrowed sharply to $8.8 million from $27.6 million in Q2 2025, dramatically outperforming management's guidance range of a $20 million to $26 million loss. GAAP gross margin reached 36.1%, exceeding guidance of 33% to 35%, while non-GAAP gross margin of 41.5% surpassed the 38% to 40% guidance range. The company ended the quarter with $2.13 billion in cash and cash equivalents, providing substantial financial runway.

The backlog surged to a record $2.36 billion, up 137% year-over-year, with the launch backlog exceeding 90 missions — the highest in company history. Management disclosed that, combined with post-quarter signings, Rocket Lab has already booked more than $1 billion in new contracts across launch and space systems in Q3 to date.

From what I see, the backlog expansion stands out as particularly important because it signals sustained demand even as the company integrates recent acquisitions.

Market Reaction and Investor Sentiment

Despite delivering record revenue and backlog figures, Rocket Lab shares fell between 2% and 6% in after-hours trading on Monday. The decline reflected a mixed reception: while the top-line beat and order-book expansion validated the company's demand story, the wider-than-expected per-share loss and forward margin guidance disappointed investors conditioned to expect flawless execution at the stock's elevated valuation multiple.

Investor sentiment entering the print had been cautiously optimistic, with options market data showing a bullish skew and a put-to-call ratio of 0.58 on near-dated contracts. The stock had rallied more than 40% from its late-July lows ahead of the report. However, the after-hours slide suggests that for a company trading at over 65 times trailing revenue, even a record quarter can fall short of market expectations when profitability concerns persist. CEO Peter Beck's acknowledgment that the Neutron launch window is "narrowing" added an additional layer of uncertainty that likely contributed to the cautious post-earnings tone.

Forward Outlook and Key Factors to Monitor

Rocket Lab issued Q3 2026 revenue guidance of $250 million to $265 million — the midpoint of $257.5 million easily exceeding the analyst consensus of approximately $235.9 million and representing year-over-year growth of around 66%. This would mark the company's sixth consecutive record revenue quarter.

However, profitability guidance came in softer than anticipated. Management expects GAAP gross margins of 29% to 31% and non-GAAP gross margins of 35% to 37%, both below the Q2 results, reflecting a shift toward lower-margin satellite platform work. The adjusted EBITDA loss is projected at $17 million to $23 million — wider than some analysts had modeled. The sequential margin compression appears tied to product mix dynamics and continued investment in the Neutron program.

The Neutron medium-lift reusable rocket remains the single most important catalyst on the horizon. Stage 1 tank production is aligned with pad delivery in Q4 2026, and the Archimedes engine program has completed more than 400 hot-fire tests. Yet Beck's caution about the narrowing launch window introduces the real possibility that the maiden flight could slide into 2027. Any further timeline adjustments would likely weigh on sentiment, given that major contract wins — including the $397 million Space Force SB-AMTI award — depend on Neutron becoming operational.

Beyond Neutron, the Iridium acquisition looms as a transformative event. Expected to close in mid-2027, the deal would add an operational 66-satellite constellation, over 2.5 million subscribers, and more than $870 million in annual revenue, positioning Rocket Lab as a vertically integrated space communications provider. Meanwhile, investors should monitor backlog conversion rates, the ramp-up of GHOST containerized launch operations in Alaska by 2027, and the integration of Mynaric and Motiv, which are expected to expand the company's space systems capabilities.

I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.

AI Tools in My Research Workflow

In my analysis of high-growth sectors like aerospace, I often turn to Tickeron's AI-powered platforms to cross-reference fundamentals and technical signals. One tool that has proven useful is the AI Trend Prediction Engine, which helps surface potential momentum shifts based on historical patterns and current data. These resources allow me to quickly validate ideas without sifting through endless spreadsheets, keeping the focus on what actually moves the needle for long-term positioning.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RKLB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


RKLB's RSI Oscillator ascends from oversold territory

The RSI Indicator for RKLB moved out of oversold territory on September 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where RKLB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RKLB advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

RKLB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RKLB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RKLB turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for RKLB moved below the 200-day moving average on August 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKLB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RKLB entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.063) is normal, around the industry mean (6.482). P/E Ratio (0.000) is within average values for comparable stocks, (56.451). RKLB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.916). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. P/S Ratio (50.000) is also within normal values, averaging (19.342).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RKLB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 41.58B. The market cap for tickers in the group ranges from 4.49 to 2.02T. SPCX holds the highest valuation in this group at 2.02T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 10%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -8%. MRLN experienced the highest price growth at 21%, while KITT experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 40%. For the same stocks of the Industry, the average monthly volume growth was -28% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 69
Price Growth Rating: 65
SMR Rating: 77
Profit Risk Rating: 74
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
RKLB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Profile
Details
Industry
N/A
Address
3881 McGowen Street
Phone
+1 714 465-5737
Employees
2600
Web
https://www.rocketlabusa.com
Interact to see
Advertisement
Shares of CRDO surged +11.90% on March 5, 2026, closing at $114.74 versus a prior close of $102.54. Primary catalyst: Strong Q3 fiscal 2026 earnings reported on March 2, with revenue of $407 million beating consensus estimates by more than $19 million and non-GAAP EPS of $1.07 surpassing forecasts by $0.29.
SPY is trading down approximately -1.30% in Friday premarket, slipping from the prior session's close of $681.31 to around $677–$678. The primary catalyst is a sharply negative February 2026 Nonfarm Payrolls report, which showed a decline of 92,000 jobs — a massive miss versus the consensus forecast of +50,000.
WAL shares dropped approximately 12% in early trading on March 6, 2026, from a prior close of ~$80.74 to roughly ~$71, marking one of the stock's sharpest single-session declines in recent months. The primary catalyst was a surprise announcement that Jefferies Financial Group declined to make a $126.4 million payment owed to Western Alliance Bank under a forbearance agreement tied to the LAM Trade Finance loan portfolio.
MRVL shares surged approximately +15% at the open on March 6, 2026, after closing at $75.68 the prior session. The primary catalyst was a strong Q4 fiscal 2026 earnings report released after the close on March 5, with non-GAAP EPS of $0.80 beating the $0.79 consensus estimate and revenue of $2.219 billion exceeding expectations.
Shares of Day One Biopharmaceuticals surged approximately +65.57% on March 6, 2026, rising from a prior close of $12.78 to an intraday price around $21.16. The primary catalyst driving the session's gains is acquisition and takeover speculation, with reports circulating that Day One may be a buyout target.
GAP shares fell approximately 13% in early trading on March 6, 2026, following the company's Q4 fiscal 2025 earnings report released after market close on March 5. Gap met Wall Street's Q4 estimates on both earnings per share and revenue, but fiscal 2026 guidance fell short of analyst expectations.
Shares of Red Cat Holdings surged approximately +22% in early Friday trading on March 6, 2026, building on a powerful week of momentum in defense drone stocks. The primary catalyst is escalating geopolitical conflict — U.S. and Israeli military strikes on Iran, which dramatically boosted investor appetite for domestic drone and defense technology companies.
The primary catalyst for the decline was the pricing of a secondary offering of roughly 9 million shares at about 22.25 dollars per share by Ingram Holdco, an affiliate of Platinum Equity, with all proceeds going to the selling shareholder and not to Ingram Micro itself. Investors often view such secondary offerings as short‑term bearish because they increase the freely tradable float and signal that a major holder is cashing out part of its stake, even if the company’s operations remain intact.
Rumble reported Q4 2025 revenue of about 27.1 million dollars, below consensus expectations near 29 million dollars and down roughly 10% year over year, confirming that top‑line momentum has stalled. GAAP EPS came in at a loss of around 0.13 dollars, missing analyst estimates by roughly 0.05 dollars and underscoring that the platform remains far from break‑even despite prior cost cuts and efficiency efforts.
Tronox’s Q4 2025 non‑GAAP EPS came in at a loss of about 0.60 dollars, missing expectations by roughly 0.02 dollars, while revenue of around 730 million dollars grew about 8% year over year, showing volume resilience but weak earnings power.
Defense budgets worldwide are surging — global military spending topped $2.2 trillion in 2023, a record high — while semiconductor demand is projected to reach a $1 trillion industry by 2030. At the intersection of these two mega-trends sits one of Tickeron's most strategically focused AI Trading Robots: the XAR, ITA, SOXL – AI Trading Agent (3 Tickers), 15min.
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.